Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Thyroid Disorders
Would you consider extending Tepezza treatment for thyroid eye disease management in patients with incomplete response?
Related Questions
Would you ever recommend radiofrequency ablation over surgery or radioiodine for a patient with an autonomously functioning thyroid nodule?
What doses of methimazole do you consider "low dose" when treating Graves' disease long-term?
Do you recommend prescribing methimazole to prevent iodinated contrast media-induced exacerbation of thyrotoxicosis in patients with pre-existing hyperthyroidism?
Would you recommend pharmacologic treatment with levothyroxine for a patient with subclinical hypothyroidism and CAD s/p stent placement even if the TSH is less than 10mIU/L, given a described association with reduced risk for major adverse cardiovascular events with treatment?
Statistically speaking, approximately what percentage of thyroid nodule FNA biopsies are Bethesda category 1 (= nondiagnostic or unsatisfactory), and what percentage are indeterminate (Bethesda category 3 and 4)?
Under what circumstances do you consider deprescribing levothyroxine in patients with mild subclinical hypothyroidism?
What is the evidence, if any, for the use of low dose naltrexone in the treatment of autoimmune thyroiditis?
Do you recommend repeat TSH testing after a patient switches from brand-name to generic levothyroxine?
In patients with Graves' disease, how many months post thyroidectomy would you anticipate seeing improvement in thyroid eye disease symptoms?
If a patient requires more than 5 mg per day of methimazole long term do you recommend alternative treatment options such as radio-iodine ablation or surgery?
